These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32574155)

  • 1. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
    Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
    Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
    Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
    Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.
    Luo B; Liu X; Zhang Q; Liang G; Zhuang Y
    Int Immunopharmacol; 2024 Oct; 140():112875. PubMed ID: 39116492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y; Xie D; Chen Z; Shen X; Wu X; Ding F; Ding S; Pan Y; Li F; Lu A; Zhang G
    J Transl Med; 2024 Jul; 22(1):604. PubMed ID: 38951906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
    Luo X; Wang H; Ji D
    Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
    Gao T; Mao Z; Li W; Pei R
    J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
    Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
    Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer.
    Nakhjavani M; Shigdar S
    Pharmacol Res; 2022 Jan; 175():106019. PubMed ID: 34861397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
    Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.